首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1022502篇
  免费   78365篇
  国内免费   2690篇
耳鼻咽喉   13208篇
儿科学   35125篇
妇产科学   29065篇
基础医学   148608篇
口腔科学   28547篇
临床医学   93055篇
内科学   198595篇
皮肤病学   23287篇
神经病学   81660篇
特种医学   39483篇
外国民族医学   305篇
外科学   152498篇
综合类   24017篇
一般理论   415篇
预防医学   80479篇
眼科学   23286篇
药学   74109篇
  3篇
中国医学   2070篇
肿瘤学   55742篇
  2018年   11011篇
  2017年   8613篇
  2016年   9757篇
  2015年   11046篇
  2014年   15143篇
  2013年   23204篇
  2012年   30731篇
  2011年   32692篇
  2010年   19526篇
  2009年   18490篇
  2008年   30602篇
  2007年   32507篇
  2006年   32949篇
  2005年   31583篇
  2004年   30847篇
  2003年   29609篇
  2002年   28596篇
  2001年   47184篇
  2000年   48206篇
  1999年   40535篇
  1998年   11575篇
  1997年   10422篇
  1996年   10456篇
  1995年   10036篇
  1994年   9337篇
  1993年   8721篇
  1992年   32395篇
  1991年   31622篇
  1990年   31130篇
  1989年   30003篇
  1988年   27281篇
  1987年   27438篇
  1986年   25533篇
  1985年   24749篇
  1984年   18594篇
  1983年   15657篇
  1982年   9506篇
  1981年   8600篇
  1979年   16958篇
  1978年   12315篇
  1977年   10416篇
  1976年   9835篇
  1975年   10251篇
  1974年   12375篇
  1973年   11884篇
  1972年   10909篇
  1971年   10132篇
  1970年   9395篇
  1969年   8729篇
  1968年   8117篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Molnár  B.  Aroca  S.  Dobos  A.  Orbán  K.  Szabó  J.  Windisch  P.  Stähli  A.  Sculean  A. 《Clinical oral investigations》2022,26(12):7135-7142
Clinical Oral Investigations - To evaluate t he long-term outcomes following treatment of RT 1 multiple adjacent gingival recessions (MAGR) using the modified coronally advanced tunnel (MCAT) with...  相似文献   
2.

Interstitial lung disease (ILD) represents a significant cause of morbidity and mortality in systemic sclerosis (SSc). The purpose of this study was to examine recirculating lymphocytes from SSc patients for potential biomarkers of interstitial lung disease (ILD). Peripheral blood mononuclear cells (PBMCs) were isolated from patients with SSc and healthy controls enrolled in the Vanderbilt University Myositis and Scleroderma Treatment Initiative Center cohort between 9/2017–6/2019. Clinical phenotyping was performed by chart abstraction. Immunophenotyping was performed using both mass cytometry and fluorescence cytometry combined with t-distributed stochastic neighbor embedding analysis and traditional biaxial gating. This study included 34 patients with SSc-ILD, 14 patients without SSc-ILD, and 25 healthy controls. CD21lo/neg cells are significantly increased in SSc-ILD but not in SSc without ILD (15.4 ± 13.3% vs. 5.8 ± 0.9%, p = 0.002) or healthy controls (5.0 ± 0.5%, p < 0.0001). While CD21lo/neg B cells can be identified from a single biaxial gate, tSNE analysis reveals that the biaxial gate is comprised of multiple distinct subsets, all of which are increased in SSc-ILD. CD21lo/neg cells in both healthy controls and SSc-ILD are predominantly tBET positive and do not have intracellular CD21. Immunohistochemistry staining demonstrated that CD21lo/neg B cells diffusely infiltrate the lung parenchyma of an SSc-ILD patient. Additional work is needed to validate this biomarker in larger cohorts and longitudinal studies and to understand the role of these cells in SSc-ILD.

  相似文献   
3.
4.
5.
Fibroblast growth factor receptors (FGFRs) are aberrantly activated through single-nucleotide variants, gene fusions and copy number amplifications in 5–10% of all human cancers, although this frequency increases to 10–30% in urothelial carcinoma and intrahepatic cholangiocarcinoma. We begin this review by highlighting the diversity of FGFR genomic alterations identified in human cancers and the current challenges associated with the development of clinical-grade molecular diagnostic tests to accurately detect these alterations in the tissue and blood of patients. The past decade has seen significant advancements in the development of FGFR-targeted therapies, which include selective, non-selective and covalent small-molecule inhibitors, as well as monoclonal antibodies against the receptors. We describe the expanding landscape of anti-FGFR therapies that are being assessed in early phase and randomised controlled clinical trials, such as erdafitinib and pemigatinib, which are approved by the Food and Drug Administration for the treatment of FGFR3-mutated urothelial carcinoma and FGFR2-fusion cholangiocarcinoma, respectively. However, despite initial sensitivity to FGFR inhibition, acquired drug resistance leading to cancer progression develops in most patients. This phenomenon underscores the need to clearly delineate tumour-intrinsic and tumour-extrinsic mechanisms of resistance to facilitate the development of second-generation FGFR inhibitors and novel treatment strategies beyond progression on targeted therapy.Subject terms: Cancer, Cancer  相似文献   
6.
7.
8.
9.
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study...  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号